Biomark Diagnostics Inc. (CSE: BUX)
Canada
· Delayed Price · Currency is CAD
0.220
-0.005 (-2.22%)
Dec 2, 2024, 4:00 PM EST
Biomark Diagnostics Company Description
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer.
The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer.
It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts.
The company was incorporated in 2014 and is headquartered in Richmond, Canada.
Biomark Diagnostics Inc.
Country | Canada |
Founded | 2014 |
Industry | Diagnostics & Research |
Sector | Healthcare |
CEO | Rashid Ahmed Bux |
Contact Details
Address: 3851 Shell Road Richmond, British Columbia V6X 2W2 Canada | |
Phone | 604 370 0779 |
Website | biomarkdiagnostics.com |
Stock Details
Ticker Symbol | BUX |
Exchange | Canadian Securities Exchange |
Fiscal Year | April - March |
Reporting Currency | CAD |
ISIN Number | CA09073K1084 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Rashid Ahmed Maula Bux B.Sc., MBA | Founder, Chief Executive Officer, President and Director |
Guoyu Huang MBA | Chief Financial Officer |
Brian Kai-Ming Cheng B.Sc., M.Sc, M.Sc. | Chief Technical Officer and Independent Director |
Dr. Jeff Haince Ph.D. | GM and Chief Scientific Officer |